CN107095974A - 一种降血糖组合物 - Google Patents
一种降血糖组合物 Download PDFInfo
- Publication number
- CN107095974A CN107095974A CN201710404774.4A CN201710404774A CN107095974A CN 107095974 A CN107095974 A CN 107095974A CN 201710404774 A CN201710404774 A CN 201710404774A CN 107095974 A CN107095974 A CN 107095974A
- Authority
- CN
- China
- Prior art keywords
- composition
- parts
- lycopene
- group
- red yeast
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 29
- 230000002218 hypoglycaemic effect Effects 0.000 title claims abstract description 11
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 claims abstract description 21
- JEVVKJMRZMXFBT-XWDZUXABSA-N Lycophyll Natural products OC/C(=C/CC/C(=C\C=C\C(=C/C=C/C(=C\C=C\C=C(/C=C/C=C(\C=C\C=C(/CC/C=C(/CO)\C)\C)/C)\C)/C)\C)/C)/C JEVVKJMRZMXFBT-XWDZUXABSA-N 0.000 claims abstract description 21
- 239000001751 lycopene Substances 0.000 claims abstract description 21
- 235000012661 lycopene Nutrition 0.000 claims abstract description 21
- OAIJSZIZWZSQBC-GYZMGTAESA-N lycopene Chemical compound CC(C)=CCC\C(C)=C\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C=C(/C)CCC=C(C)C OAIJSZIZWZSQBC-GYZMGTAESA-N 0.000 claims abstract description 21
- 229960004999 lycopene Drugs 0.000 claims abstract description 21
- 229940026314 red yeast rice Drugs 0.000 claims abstract description 21
- ZCIHMQAPACOQHT-ZGMPDRQDSA-N trans-isorenieratene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/c1c(C)ccc(C)c1C)C=CC=C(/C)C=Cc2c(C)ccc(C)c2C ZCIHMQAPACOQHT-ZGMPDRQDSA-N 0.000 claims abstract description 21
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims abstract description 19
- 150000002148 esters Chemical class 0.000 claims abstract description 16
- 239000003814 drug Substances 0.000 claims abstract description 10
- 235000013305 food Nutrition 0.000 claims abstract description 10
- 239000000463 material Substances 0.000 claims description 3
- 239000003472 antidiabetic agent Substances 0.000 claims description 2
- 241000196324 Embryophyta Species 0.000 claims 1
- -1 alcohol ester Chemical class 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- 150000003431 steroids Chemical class 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract description 7
- 230000036541 health Effects 0.000 abstract description 5
- 238000002360 preparation method Methods 0.000 abstract description 4
- 239000002994 raw material Substances 0.000 abstract description 3
- 238000012360 testing method Methods 0.000 abstract description 3
- 231100000957 no side effect Toxicity 0.000 abstract description 2
- 239000008280 blood Substances 0.000 description 23
- 210000004369 blood Anatomy 0.000 description 23
- 239000011651 chromium Substances 0.000 description 16
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 12
- 239000008103 glucose Substances 0.000 description 12
- 241000700159 Rattus Species 0.000 description 8
- 230000000694 effects Effects 0.000 description 7
- 210000000496 pancreas Anatomy 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 210000003462 vein Anatomy 0.000 description 4
- BOVGTQGAOIONJV-BETUJISGSA-N 1-[(3ar,6as)-3,3a,4,5,6,6a-hexahydro-1h-cyclopenta[c]pyrrol-2-yl]-3-(4-methylphenyl)sulfonylurea Chemical group C1=CC(C)=CC=C1S(=O)(=O)NC(=O)NN1C[C@H]2CCC[C@H]2C1 BOVGTQGAOIONJV-BETUJISGSA-N 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 230000003914 insulin secretion Effects 0.000 description 3
- 210000004153 islets of langerhan Anatomy 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 238000011552 rat model Methods 0.000 description 3
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 3
- 206010003694 Atrophy Diseases 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 241000209094 Oryza Species 0.000 description 2
- 235000007164 Oryza sativa Nutrition 0.000 description 2
- 241000700157 Rattus norvegicus Species 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000037444 atrophy Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 210000005252 bulbus oculi Anatomy 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 235000012721 chromium Nutrition 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000004064 dysfunction Effects 0.000 description 2
- 238000000855 fermentation Methods 0.000 description 2
- 230000004151 fermentation Effects 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 238000003304 gavage Methods 0.000 description 2
- 238000005469 granulation Methods 0.000 description 2
- 230000003179 granulation Effects 0.000 description 2
- 235000013402 health food Nutrition 0.000 description 2
- 201000001421 hyperglycemia Diseases 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 239000002398 materia medica Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 235000009566 rice Nutrition 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 2
- 235000020985 whole grains Nutrition 0.000 description 2
- SWLAMJPTOQZTAE-UHFFFAOYSA-N 4-[2-[(5-chloro-2-methoxybenzoyl)amino]ethyl]benzoic acid Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(C(O)=O)C=C1 SWLAMJPTOQZTAE-UHFFFAOYSA-N 0.000 description 1
- 208000001889 Acid-Base Imbalance Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 102000040350 B family Human genes 0.000 description 1
- 108091072128 B family Proteins 0.000 description 1
- 229940123208 Biguanide Drugs 0.000 description 1
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
- 240000000560 Citrus x paradisi Species 0.000 description 1
- 206010010071 Coma Diseases 0.000 description 1
- 208000005156 Dehydration Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 206010014418 Electrolyte imbalance Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 206010018473 Glycosuria Diseases 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 235000007688 Lycopersicon esculentum Nutrition 0.000 description 1
- 241000228347 Monascus <ascomycete fungus> Species 0.000 description 1
- 241000235342 Saccharomycetes Species 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 240000003768 Solanum lycopersicum Species 0.000 description 1
- 244000061458 Solanum melongena Species 0.000 description 1
- ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 1
- 229940100389 Sulfonylurea Drugs 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 206010000891 acute myocardial infarction Diseases 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000003035 anti-peroxidant effect Effects 0.000 description 1
- 230000036523 atherogenesis Effects 0.000 description 1
- 150000004283 biguanides Chemical class 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 239000010495 camellia oil Substances 0.000 description 1
- 210000004413 cardiac myocyte Anatomy 0.000 description 1
- 235000021466 carotenoid Nutrition 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 1
- 229910052804 chromium Inorganic materials 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 229940090124 dipeptidyl peptidase 4 (dpp-4) inhibitors for blood glucose lowering Drugs 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 125000004185 ester group Chemical group 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000001508 eye Anatomy 0.000 description 1
- 235000002864 food coloring agent Nutrition 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 239000003316 glycosidase inhibitor Substances 0.000 description 1
- 230000003118 histopathologic effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229950004994 meglitinide Drugs 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 230000000050 nutritive effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000001151 other effect Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000003014 reinforcing effect Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 229960001052 streptozocin Drugs 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 150000001467 thiazolidinediones Chemical class 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 230000008736 traumatic injury Effects 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L31/00—Edible extracts or preparations of fungi; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L31/00—Edible extracts or preparations of fungi; Preparation or treatment thereof
- A23L31/10—Yeasts or derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
- A23L33/11—Plant sterols or derivatives thereof, e.g. phytosterols
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23P—SHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
- A23P10/00—Shaping or working of foodstuffs characterised by the products
- A23P10/20—Agglomerating; Granulating; Tabletting
- A23P10/28—Tabletting; Making food bars by compression of a dry powdered mixture
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23P—SHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
- A23P10/00—Shaping or working of foodstuffs characterised by the products
- A23P10/30—Encapsulation of particles, e.g. foodstuff additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/01—Hydrocarbons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/062—Ascomycota
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/062—Ascomycota
- A61K36/064—Saccharomycetales, e.g. baker's yeast
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/10—Preparation or pretreatment of starting material
- A61K2236/19—Preparation or pretreatment of starting material involving fermentation using yeast, bacteria or both; enzymatic treatment
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Polymers & Plastics (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
本发明公开了一种降血糖药物组合物和保健功能性食品。该组合物按重量份计主要由植物甾醇酯60‑70份、红曲35‑50份、番茄红素2‑5、富铬酵母1份制成。优选配比为植物甾醇酯65份、红曲40份、番茄红素3份、富铬酵母1份。本组合物经试验证明具有显著的降血糖作用，且原料价廉易得，制备方法简单，安全无副作用，可用于糖尿病日常治疗保健。
Description
技术领域
本发明涉及一种降血糖药物组合物和保健功能性食品。
背景技术
目前，糖尿病的发病率逐年上升，我国的糖尿病发病率目前为9.7％，位居世界第二。糖尿病是一种由于胰岛素分泌缺陷或胰岛素作用障碍所致的以高血糖为特征的代谢性疾病。持续高血糖与长期代谢紊乱等可导致全身组织器官，特别是眼、肾、心血管及神经系统的损害及其功能障碍和衰竭。严重者可引起失水，电解质紊乱和酸碱平衡失调等急性并发症酮症酸中毒和高渗昏迷。临床治疗的药物，根据作用效果不同，可分为促胰岛素分泌剂，例如磺脲类、格列奈类、DPP-4抑制剂；和非促胰岛素分泌剂，例如双胍类、噻唑烷二酮类、a-糖苷酶抑制剂等。但其中大部分的降糖药物存在不同程度的副作用且治疗成本高。因此，研发安全无副作用、价格低廉的降血糖保健药品或食品具有较大社会需求。
植物甾醇酯为植物甾醇与来自植物油的脂肪酸发生酯化反应而生成，是一种新资源食品用料，可用作辅助降血脂功能保健食品。
富铬酵母就是含有大量铬元素的酵母菌。富铬酵母不仅铬含量高，而且还含有丰富蛋白质、核酸、糖原、脂肪、B族维生素和其他多种微量元素，营养保健价值高，可用于营养保健产品，还可应用于食品加工与营养强化。
番茄红素属于类胡萝卜素类脂溶性色素，广泛存在于番茄、西柚等水果中。现代研究证实，番茄红素可以改善成纤维细胞中自由基清除酶活力，提高成纤维细胞对紫外损伤的抗氧化能力，对抗脂质过氧化对心脑血管内皮产生的损伤，减轻动脉粥样硬化形成，抑制心肌细胞肥大，对急性心肌梗死及高血糖所导致的内皮祖细胞功能障碍具有保护作用。番茄红素正快速成为抗衰老、预防老年病心脑血管病变及神经退行性病变的保健食品。食品安全性评价结果显示，ICR小鼠对番茄红素最大可耐受灌胃剂量高于人体推荐食用量100倍，属于实际无毒级。
红曲是以大米为原料，经红曲霉发酵而成的一种紫红色米曲。红曲的发明至今已有一千多年的历史。广泛用于酿酒、食品着色、食品发酵及中药等方面。红曲也是一味传统中药,在《本草纲目》、《本草从新》等中均有记载。本品味甘、性温，具有活血化瘀、健脾消食功能。主治产后恶露不净、瘀滞腹痛、赤白下痢、跌打损伤等症状。现代研究也表明，红曲还有降低血清胆固醇及防癌等功效。
发明内容
本发明提供了一种可供日常治疗保健使用的降血糖组合物。该组合物按重量份计主要由植物甾醇酯60-70份、红曲35-50份、番茄红素2-5、富铬酵母1份制成。
优选配比为：植物甾醇酯65份、红曲40份、番茄红素3份、富铬酵母1份。
所述组合物可用于制备降血糖药物或保健功能性食品。
本组合物经试验证明具有显著的降血糖作用，且原料价廉易得，制备方法简单，安全无副作用，可用于糖尿病日常治疗保健。
具体实施方式
下面结合实施例对本发明做进一步的说明。
实施例1：对实验性2型糖尿病大鼠的影响
取红曲40克、番茄红素3克、富铬酵母1克、植物甾醇酯65克，混合研匀，备用。
健康Wistar大鼠(SPF级)，雄性，体重180-220g(由南方医科大学实验动物中心提供)，自由饮水进食，随机分为正常对照组和造模组，造模组按如下方法建立模型：
正常组大鼠每天灌胃蒸馏水，高脂组大鼠每天按1ml/100gBW量早晚灌胃脂肪乳。连续2周后，动物禁食不禁水24h，正常对照组尾静脉注射生理盐水，其余均按30mg/kgBW剂量，尾静脉注射链脲佐菌素溶液。给药48h后，禁食不禁水12h，每隔3小时眼球后静脉丛取血，按照血糖测定试剂盒操作测定空腹血糖值，连续测定3次，空腹血糖值≥16.8mmol/L的为造模成功大鼠。
造模成功后，将模型组动物随机分为模型对照组、格列奇特组、供试样品高、中、低剂量组和红曲、番茄红素、富铬酵母、植物甾醇酯组，按表1连续给药1周。
表1实验分组与给药
| 组别 | 动物数(只) | 给药量(mg/kgBW) |
| 正常对照组 | 10 | - |
| 模型对照组 | 10 | - |
| 格列奇特组 | 10 | 35.5 |
| 高剂量组 | 10 | 200 |
| 中剂量组 | 10 | 100 |
| 低剂量组 | 10 | 50 |
| 红曲 | 10 | 200 |
| 番茄红素 | 10 | 20 |
| 富铬酵母 | 10 | 20 |
| 植物甾醇酯 | 10 | 200 |
末次给药后，动物禁食不禁水12h，眼球后静脉丛取血，按照试剂盒的方法分别测定血糖值。统计分析并比较各组血糖值及给药前后血糖值的变化情况。
大鼠脱颈处死后，取胰腺用10％甲醛溶液固定，常规包埋，HE染色，光镜下观察胰岛细胞形态。
结果见表2，注射STZ后大鼠血糖上升，72h后空腹血糖值≥16.8mmol/L，说明糖尿病模型成功。给药后，格列奇特组、给药高、中个剂量组的血糖值与模型组血糖值比较，均有非常显著的差异(P<0.01)；低剂量组与其余四组与模型组血糖值有显著性差异(P<0.05)。
各组给药前血糖和给药后血糖的T检验显示，格列奇特组和给药组高、中剂量组给药前后的血糖值比较，均具有非常显著的差异(P<0.01)，低剂量组与其余四组给药前后的血糖值比较，无具有显著性差异(P<0.05)。以上结果表明，该药物组合物相互之间具有协同作用，可以共同起来协同降低实验性2型糖尿病大鼠的血糖的作用。
表2给药后血糖值比较
*P<0.05,**p<0.01,与模型组比较；△P<0.05,△△p<0.01与给药前比较。
另外，从病理组织切片观察，正常大鼠的胰岛细胞形态饱满，界限清楚，胰岛细胞排列整齐。糖尿病模型组大鼠的胰岛明显萎缩，轮廓不饱满，胰岛中细胞密度降低，胰岛细胞空泡变性。与糖尿病模型组比较，该组合物各剂量治疗组大鼠的胰岛萎缩的情况均有所改善，胰岛面积增加，胰岛中细胞密度增大，而后四组的改善不明显，亦说明可以协同起到对胰岛细胞的保护作用。
实施例2：不同配比组合物对实验性2型糖尿病大鼠的影响
分别取红曲、番茄红素、富铬酵母、植物甾醇酯，按照不同的质量份配比分成三份。组合物①：红曲35克、番茄红素2克、富铬酵母1克、植物甾醇酯60克；②红曲50克、番茄红素5克、富铬酵母1克、植物甾醇酯70克；③红曲40克、番茄红素3克、富铬酵母1克、植物甾醇酯65克。分别混合研匀，备用。
按照实施例1所述方法，取健康Wistar大鼠(SPF级)，雄性，体重180-220g(由南方医科大学实验动物中心提供)，自由饮水进食，随机分为正常对照组和造模组，组合物①、②、③组，进行实验，样品组给药量均为100mg/kgBW。结果表明在以下质量份的各物质组成：红曲35-50份、番茄红素2-5、富铬酵母1份、植物甾醇酯60-70份，该组合物具有较好的降血糖效果。具体结果如下：
表3不同配比组合物的降糖效果比较
*P<0.05,**p<0.01,与模型组比较；△P<0.05,△△p<0.01与给药前比较。
实施例3组合物胶囊与片的制备
取红曲400克、番茄红素30克、富铬酵母10、植物甾醇酯650克，混合均匀，加入500克淀粉，再混合均匀，制粒，整粒，干燥，加入0.5％的微粉硅胶与0.5％的硬脂酸镁，混匀，按0.5克/粒的装量，装入胶囊，即得组合物胶囊。
取红曲400克、番茄红素30克、富铬酵母1、植物甾醇酯650克，混合均匀，加入500克淀粉，再混合均匀，制粒，整粒，干燥，加入0.5％的微粉硅胶与0.5％的硬脂酸镁，混匀，按0.5克/片规格压片，即得组合物片。
实施例4组合物软胶囊的制备
取红曲4000克、番茄红素300克、富铬酵母100、植物甾醇酯6500克，混合均匀，然后加入相同质量的大豆油或茶油，用胶体磨研匀，作为软胶囊内容物，按0.6克/粒，制成软胶囊。
Claims (4)
1.一种降血糖组合物，其特征在于，该组合物按重量份计主要由以下组份制成：植物甾醇酯60-70份、红曲35-50份、番茄红素2-5、富铬酵母1份。
2.如权利要求1所述组合物，其特征在于，其组份配比为：植物甾醇酯65份、红曲40份、番茄红素3份、富铬酵母1份。
3.权利要求1或2所述组合物，其特征在于，所述组合物在制备降血糖药物或保健功能性食品中的应用。
4.权利要求3所述组合物，其特征在于，所述组合物与药物或食品辅料制成适用于临床使用或食用的剂型。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710404774.4A CN107095974A (zh) | 2017-06-01 | 2017-06-01 | 一种降血糖组合物 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710404774.4A CN107095974A (zh) | 2017-06-01 | 2017-06-01 | 一种降血糖组合物 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN107095974A true CN107095974A (zh) | 2017-08-29 |
Family
ID=59659160
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710404774.4A Pending CN107095974A (zh) | 2017-06-01 | 2017-06-01 | 一种降血糖组合物 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107095974A (zh) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114504617A (zh) * | 2022-03-11 | 2022-05-17 | 汤臣倍健股份有限公司 | 具有辅助降血脂功效的组合物及其应用 |
| CN116327814A (zh) * | 2022-09-08 | 2023-06-27 | 健合香港有限公司 | 一种降血脂、降胆固醇的组合物及其制备方法和用途 |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS55155056A (en) * | 1979-05-24 | 1980-12-03 | Shikamitsu Honsha:Kk | Production of yellow coloring matter for food using berberine as raw material |
| CN1308955A (zh) * | 2000-12-20 | 2001-08-22 | 郭兴华 | 一种防治心脑血管疾病的天然组合物及其应用 |
| CN101035594A (zh) * | 2004-08-09 | 2007-09-12 | 酶学技术有限公司 | 用于糖尿病患者的食品 |
| CN101953442A (zh) * | 2009-12-23 | 2011-01-26 | 济南圣泉唐和唐生物科技有限公司 | 一种具有降血糖功能的保健品 |
| CN102885897A (zh) * | 2012-10-10 | 2013-01-23 | 湖北省宏源药业有限公司 | 一种具有辅助降血糖功能组合物及其制备方法 |
| CN104147132A (zh) * | 2014-08-20 | 2014-11-19 | 哈尔滨顺亿堂医药生物科技开发有限公司 | 能够降低血糖调节胰岛素分泌的软胶囊及制作方法 |
-
2017
- 2017-06-01 CN CN201710404774.4A patent/CN107095974A/zh active Pending
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS55155056A (en) * | 1979-05-24 | 1980-12-03 | Shikamitsu Honsha:Kk | Production of yellow coloring matter for food using berberine as raw material |
| CN1308955A (zh) * | 2000-12-20 | 2001-08-22 | 郭兴华 | 一种防治心脑血管疾病的天然组合物及其应用 |
| CN101035594A (zh) * | 2004-08-09 | 2007-09-12 | 酶学技术有限公司 | 用于糖尿病患者的食品 |
| CN101953442A (zh) * | 2009-12-23 | 2011-01-26 | 济南圣泉唐和唐生物科技有限公司 | 一种具有降血糖功能的保健品 |
| CN102885897A (zh) * | 2012-10-10 | 2013-01-23 | 湖北省宏源药业有限公司 | 一种具有辅助降血糖功能组合物及其制备方法 |
| CN104147132A (zh) * | 2014-08-20 | 2014-11-19 | 哈尔滨顺亿堂医药生物科技开发有限公司 | 能够降低血糖调节胰岛素分泌的软胶囊及制作方法 |
Non-Patent Citations (1)
| Title |
|---|
| 清大社区平台: "【济生源百万高新急招】：小会讲师/诊疗会专家/餐推讲师/会销讲师/招商总监/招商人员/扶商人员【名企招聘】", 《HTTPS://MP.WEIXIN.QQ.COM/S/IWAENBG1R7FIBHC9LK9FMQ》 * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114504617A (zh) * | 2022-03-11 | 2022-05-17 | 汤臣倍健股份有限公司 | 具有辅助降血脂功效的组合物及其应用 |
| CN116327814A (zh) * | 2022-09-08 | 2023-06-27 | 健合香港有限公司 | 一种降血脂、降胆固醇的组合物及其制备方法和用途 |
| WO2024050864A1 (zh) * | 2022-09-08 | 2024-03-14 | 健合香港有限公司 | 一种降血脂、降胆固醇的组合物及其制备方法和用途 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102406860B (zh) | 预防和治疗糖尿病的组合物、其制备方法及应用 | |
| CN101467575B (zh) | 一种降糖调脂健身营养茶及其制作方法 | |
| CN106244371B (zh) | 一种降血糖黄精葡萄保健酒及其生产工艺 | |
| CN108392519A (zh) | 一种降血糖组合物及其制备和应用 | |
| CN107951935A (zh) | 一种葛根枳椇子破壁组合物及其制备方法和应用 | |
| CN107581543A (zh) | 一种降血糖复合冲剂 | |
| CN105341893A (zh) | 一种辅助降血糖的组合物及应用 | |
| Frost | Three popular medicinal mushroom supplements: A review of human clinical trials | |
| CN107095974A (zh) | 一种降血糖组合物 | |
| EP3881685A1 (en) | Ceratonia siliqua fruit composition and preparation method therefor and use thereof | |
| CN104027494B (zh) | 一种具有延缓衰老及保健功效的中药组合物 | |
| CN102266388A (zh) | 一种用于2型糖尿病及并发症预防和治疗的药物组合物 | |
| CN111357982A (zh) | 沙棘复合发酵液及其制备方法、保健饮品、植物酵素 | |
| CN103920140B (zh) | 一种人用降糖减肥降脂复方制剂 | |
| CN110074392A (zh) | 一种解酒保肝养胃护肠组合物及其制备方法 | |
| CN102652561A (zh) | 治疗微病症或辅助药物康复病体的植物蛋白食品及生产方法 | |
| CN108324803A (zh) | 辅助降血糖的固体饮料及其制备方法 | |
| CN101120750A (zh) | 银杏蜂产品的制备方法 | |
| CN106798854A (zh) | 余甘桑叶片及其制备方法 | |
| CN107616491A (zh) | 一种用于防治糖尿病的功能食品 | |
| CN105106721A (zh) | 一种具有降糖功效的保健品 | |
| Tarigan et al. | The Impact of Tomato Juice on Reducing Blood Sugar Levels at Diabetes Mellitus Patients | |
| CN111357902A (zh) | 一种降血脂功能性饮料及其制备方法 | |
| CN102274285A (zh) | 一种用于2型糖尿病及并发症的药物组合物 | |
| CN107821538A (zh) | 一种降血糖的饼干及其制备方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20170829 |